Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database

Anderson, William F.; Chatterjee, Nilanjan; Ershler, William B.; Brawley, Otis W.

doi:10.1023/a:1020299707510

Cited by 498 publications

(383 citation statements)

References 42 publications

Supporting

Mentioning

356

Contrasting

Unclassified

Order By: Relevance

“…Agespecific incidence rates were calculated by fourteen 5-year age groups (ages 20-24, 25-29 , …, 80-84, and 85+ years). Kernel density estimation produced "smoothed" age distribution curves at diagnosis (or density plots), as previously described [7]. In brief, the kernel smoother estimated the underlying probability density function for breast cancer incidence by age at diagnosis in single years.…”

Section: Methodsmentioning

confidence: 99%

Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program

Anderson

Luo

Chatterjee

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

Background-In 2001, the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program established Residual Tissue Repositories (RTR) in the Hawaii, Iowa, and Los Angeles Tumor Registries to collect discarded tissue blocks from pathologic laboratories within their catchment areas. To validate the utility of the RTR for supplementing SEER's central database, we assessed human epidermal growth factor receptor-2 (HER2) and estrogen receptor expression (ER) in a demonstration project.

show abstract

Section: Methodsmentioning

confidence: 99%

Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program

Anderson

Luo

Chatterjee

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…The characteristics of these women are presented in Table 1. In Ireland, primary therapy for 27 One-third of patients in the cohort of women identified were above the age of 75, reflecting the overrepresentation of elderly patients in the HSE-PCRS database but also the higher rates of estrogen receptor-positive breast cancer seen in this population. In the year before tamoxifen initiation antidepressant and antipsychotic prescribing rates are comparable to the mean yearly prescribing rates for these drugs in the total HSE-PCRS population of women over the age of 35.…”

Section: Study Cohortmentioning

confidence: 99%

Early discontinuation of tamoxifen

Barron

Connolly

Bennett

et al. 2007

Cancer

259

248

View full text Add to dashboard Cite

BACKGROUND.Five years of treatment provides the optimum duration of tamoxifen therapy for the prevention of breast cancer recurrence and mortality. Durations of adjuvant tamoxifen therapy less than 5 years are associated with poorer outcomes for breast cancer patients. The purpose of the study was to assess rates of tamoxifen nonpersistence (early discontinuation) in women aged 35 years or older using prescription refill data from a national prescribing database.METHODS.A cohort of 2816 women commencing tamoxifen as initial hormonal therapy was identified between January 2001 and January 2004. The cumulative tamoxifen persistence rate was calculated for these women and the relation between nonpersistence and clinical and demographic variables assessed.RESULTS.Within 1 year of commencing treatment the cumulative tamoxifen nonpersistence rate was 22.1%. This is twice the rate of treatment discontinuation observed in other studies by this time. By the end of follow‐up at 3.5 years, the cumulative nonpersistence rate had increased to 35.2%. Determinants of nonpersistence identified included age and a history of antidepressant use.CONCLUSIONS.The rate of nonpersistence with tamoxifen therapy is higher than previously reported. This study demonstrates that persistence with tamoxifen cannot be assumed and raises concerns about persistence with other oral hormonal therapies for breast cancer and oral antineoplastics in general. Oncologists need to identify those at risk of nonpersistence and develop strategies to combat this barrier to treatment success. Cancer 2007. © 2007 American Cancer Society.

show abstract

“…In general, ERα expression is higher in tumors of older patients, and older or postmenopausal women are more likely to have ER+ tumors than younger women [88,115,116]. However, several studies failed to find significant correlations between ERβ expression and patient age [88,103,104,107].…”

Section: Clinical Correlations Between Erβ Expression and Patient Popmentioning

confidence: 99%

ERβ in breast cancer—Onlooker, passive player, or active protector?

2008

View full text Add to dashboard Cite

The role of estrogen exposure in breast cancer risk is well-documented, and both estrogen synthesis and actions through the estrogen receptor (ER) have been targeted by therapies to control hormonedependent breast cancer. The discovery of a second ER form and its therapeutic implications sparked great interest. Both the original ERα and the more recently identified ERβ subtypes bind and respond similarly to many physiological and pharmacological ligands. However, differences in phytoestrogen binding have been noted, and subtype-specific ligands have been developed. Cell-based assays show that ERβ and its variants are generally less active on gene transcription than ERα, and may influence ERα activity; however, both gene-and cell-specific responses occur, and nongenomic activities are less well explored. Specific ligands, and methods to disrupt or eliminate receptor subtype expression in animal and cell models, demonstrate that the ERs have both overlapping and distinct biological functions. Overall, in cell-based studies, ERα appears to play a predominant role in cell proliferation, and ERβ is suggested to be antiproliferative.The potential for distinct populations of breast tumors to be identified based on ER subtype expression, and to exhibit distinct clinical behaviors, is of greatest interest. Several studies suggest that the majority of ER-positive tumors contain both subtypes, but that some tumors contain only ERβ and may have distinct clinical behaviors and responses. Expression of ERβ together with ERα favors positive responses to endocrine therapy in most studies, and additional studies to determine if the addition of ERβ to ERα as a tumor marker is of clinical benefit are warranted. In contrast, the positive association between ERβ and HER2 expression in high-grade ERα-negative breast cancer does not favor positive responses to endocrine therapy. Expression of ERβ in specific clinical subpopulations, and the potential for therapies targeting ERβ specifically, is discussed.

show abstract

Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database

Abstract: ERalpha exhibited bimodal age frequency distribution with a dichotomous pattern for age-specific rates, racial, and prognostic factor profiles. Menopause had a greater effect on ERN than ERP. Possible implications for breast carcinogenesis and cancer prevention are discussed in the text.

Cited by 498 publications

References 42 publications

Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program

Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program

Early discontinuation of tamoxifen

ERβ in breast cancer—Onlooker, passive player, or active protector?

Contact Info

Product

Resources

About